Entelev®, Cantron®, Sheridan’s formula, JS-114, JS-101, 126-F, Jim’s Juice, Quantrol, Protocel®
Unproven alternative treatment which contains a variety of ingredients depending on manufacturer (e.g catechol, nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, crocinic acid, and various minerals and vitamins). Patients use this product to prevent and treat cancer, HIV/AIDS, epilepsy, Alzheimer's, and other immunologic and degenerative diseases.
Proposed by James Sheridan in the 1930s, CanCell® is believed to balance the vibrational frequency of cancer cells, thereby returning them to their healthy state. This theory is not supported by scientific evidence (1) (2).
Manufacturers of CanCell® discourage combining CanCell® with conventional oncology treatments (1). Patients should avoid this product.
- Alzheimer's disease
- Cancer treatment
- Cystic fibrosis
- HIV and AIDS
- Multiple sclerosis
- Systemic lupus erythematosus (SLE)
- Viral infections
- Nitric acid
- Sodium sulfite
- Potassium hydroxide
- Sulfuric acid
- Crocinic acid
Mechanism of Action
Manufacturers of CanCell® and Cantron® offer different theories explaining their products' anticancer activities: Cancer cells function at a “critical point” of cellular respiration, above which normal cells function aerobically, and below which abnormal anaerobic cells are destroyed as foreign matter. The catechol component is claimed to inhibit cellular respiration in cancer cells so that they might fall from the “critical point” to a primitive state and self-destruct. In addition, CanCell® is thought to balance the vibration frequency of cancer cells, returning them to a normal state. The manufacturers of Cantron® claim that imbalance in cellular respiration results in cellular damage. Cantron® is believed to help maintain balance through the electrolyte and antioxidant properties of its hydroxyquinone and catechol components. Neither set of claims is substantiated by scientific data.
No formal pharmacokinetics studies exist. The manufacturer states that the product is absorbed orally, sublingually, topically, and rectally.
Literature Summary and Critique
Although the manufacturers of CanCell® maintain that extensive studies in mice and humans document its efficacy (3), no data have been published in peer-reviewed journals. In 1978 and 1980, the National Cancer Institute (NCI) conducted animal studies with CanCell® and found that the product lacked antitumor activity. The NCI's In Vitro Anticancer Drug Discovery Program evaluated CanCell® in 1990-1, also with negative results (1). Neither study was published. It was determined that no further research on CanCell®/Entelev® was warranted.
Dosage (Inside MSKCC Only)
This field is only visible to only Inside MSKCC users.